EMA response to ECCO position statement on biosimilars

Comment

Silvio Danese et al. J Crohns Colitis. 2014 Mar.

. 2014 Mar;8(3):259.

doi: 10.1016/j.crohns.2014.01.017. Epub 2014 Feb 7.

No abstract available

Comment on

ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
Danese S, Gomollon F; Governing Board and Operational Board of ECCO. Danese S, et al. J Crohns Colitis. 2013 Aug;7(7):586-9. doi: 10.1016/j.crohns.2013.03.011. Epub 2013 Apr 25. J Crohns Colitis. 2013. PMID: 23623738
ECCO position challenged by European drug regulators.
Kurki P, Bielsky MC; Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP) of Committee for Medicinal Products for Human Use (CHMP). Kurki P, et al. J Crohns Colitis. 2014 Mar;8(3):258. doi: 10.1016/j.crohns.2014.01.022. Epub 2014 Feb 14. J Crohns Colitis. 2014. PMID: 24530132 No abstract available.